

MAIL STOP AMENDMENT

Attorney Docket No. 26964U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SCHMIDT

Conf. No.:

6178

Serial No.:

10/549,631

Examiner:

BASQUILL, S.M.

Filed:

November 7, 2005

Art Unit:

1612

For:

PROCESS FOR PREPARING CRYSTALLINE CICLESONIDE WITH

DEFINED PARTICLE SIZE

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Commissioner:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter, one (1) page; and
- Response to Restriction/Election Requirement, four (4) pages. (2)

In the event this paper is not timely filed, Applicants petition for an appropriate extension of time. Please charge any fee deficiency or credit any overpayment to Deposit Account No. 14-0112:

Respectfully submitted,

THE NATH LAW GROUP

Date: February 17, 2009 THE NATH LAW GROUP 112 South West Street Alexandria, Virginia 22314

Tel: (703) 548-6284 Fax: (703) 683-8396 GarVM. Nath

Registration No. 26,965 Joshua B. Goldberg Registration No. 44,126 Sheldon M. McGee Registration No. 50,454

Customer No. 34375

MAIL STOP AMENDMENT

Attorney Docket No. 26964U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SCHMIDT

Confirmation No. 6178

Serial No: 10/549,631

Group Art Unit: 1612

Filed: November 7, 2005

Examiner: BASQUILL, S.M.

For:

PROCESS FOR PREPARING CRYSTALLINE CICLESONIDE WITH DEFINED

PARTICLE SIZE

RESPONSE TO RESTRICTION REQUIREMENT

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This paper is submitted responsive to the Official Action dated January 16, 2009, making a Response due on or before February 16, 2009. As February 16, 2009 is a federal holiday, pursuant to MPEP § 710.01(a), this reply is timely if it is filed on the next succeeding business day. As such, this Response is timely filed.

REMARKS

Claims 1-27 are pending in the captioned application. The Examiner required restriction under 35 U.S.C. §§ 121 and 372, as follows:

Group I:

Claims 1-18, drawn to a process for preparing ciclesonide.

Group II:

Claims 19-27, drawn to ciclesonide and compositions

containing ciclesonide.